SG188639A1 - Factor ii and fibrinogen for treatment of haemostatic disorders - Google Patents
Factor ii and fibrinogen for treatment of haemostatic disorders Download PDFInfo
- Publication number
- SG188639A1 SG188639A1 SG2013021498A SG2013021498A SG188639A1 SG 188639 A1 SG188639 A1 SG 188639A1 SG 2013021498 A SG2013021498 A SG 2013021498A SG 2013021498 A SG2013021498 A SG 2013021498A SG 188639 A1 SG188639 A1 SG 188639A1
- Authority
- SG
- Singapore
- Prior art keywords
- fibrinogen
- combination
- blood
- fil
- clotting factor
- Prior art date
Links
- 102000008946 Fibrinogen Human genes 0.000 title claims abstract description 120
- 108010049003 Fibrinogen Proteins 0.000 title claims abstract description 120
- 229940012952 fibrinogen Drugs 0.000 title claims abstract description 120
- 238000011282 treatment Methods 0.000 title claims abstract description 86
- 229940030225 antihemorrhagics Drugs 0.000 title description 36
- 230000000025 haemostatic effect Effects 0.000 title description 23
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims abstract description 75
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims abstract description 75
- 239000003114 blood coagulation factor Substances 0.000 claims abstract description 74
- 230000023597 hemostasis Effects 0.000 claims abstract description 26
- 230000001771 impaired effect Effects 0.000 claims abstract description 13
- 210000004369 blood Anatomy 0.000 claims description 93
- 239000008280 blood Substances 0.000 claims description 93
- 238000000034 method Methods 0.000 claims description 57
- 108090000190 Thrombin Proteins 0.000 claims description 40
- 229960004072 thrombin Drugs 0.000 claims description 39
- 208000032843 Hemorrhage Diseases 0.000 claims description 33
- 230000015271 coagulation Effects 0.000 claims description 33
- 238000005345 coagulation Methods 0.000 claims description 33
- 206010053567 Coagulopathies Diseases 0.000 claims description 29
- 208000034158 bleeding Diseases 0.000 claims description 23
- 230000000740 bleeding effect Effects 0.000 claims description 23
- 230000035602 clotting Effects 0.000 claims description 19
- 206010060906 Dilutional coagulopathy Diseases 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 16
- 208000015294 blood coagulation disease Diseases 0.000 claims description 11
- 206010053476 Traumatic haemorrhage Diseases 0.000 claims description 10
- 208000031169 hemorrhagic disease Diseases 0.000 claims description 10
- 238000011260 co-administration Methods 0.000 claims description 6
- 230000006641 stabilisation Effects 0.000 claims description 5
- 238000011105 stabilization Methods 0.000 claims description 5
- 208000009292 Hemophilia A Diseases 0.000 claims description 3
- 238000012423 maintenance Methods 0.000 claims description 3
- 230000035761 normovolemia Effects 0.000 claims description 3
- 208000018525 Postpartum Hemorrhage Diseases 0.000 claims description 2
- 230000001435 haemodynamic effect Effects 0.000 claims description 2
- 208000031220 Hemophilia Diseases 0.000 claims 1
- 101001052793 Homo sapiens GDP-L-fucose synthase Proteins 0.000 claims 1
- 102000050085 human TSTA3 Human genes 0.000 claims 1
- 229940024790 prothrombin complex concentrate Drugs 0.000 description 40
- 108010074864 Factor XI Proteins 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
- 208000035475 disorder Diseases 0.000 description 25
- 230000000694 effects Effects 0.000 description 23
- 238000013169 thromboelastometry Methods 0.000 description 21
- 238000010790 dilution Methods 0.000 description 20
- 239000012895 dilution Substances 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- 108010072035 antithrombin III-protease complex Proteins 0.000 description 18
- 239000011780 sodium chloride Substances 0.000 description 18
- 239000000535 fibrinogen concentrate Substances 0.000 description 17
- 210000002381 plasma Anatomy 0.000 description 17
- 108010073385 Fibrin Proteins 0.000 description 16
- 102000009123 Fibrin Human genes 0.000 description 16
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 16
- 229950003499 fibrin Drugs 0.000 description 16
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 208000014674 injury Diseases 0.000 description 14
- 206010059484 Haemodilution Diseases 0.000 description 13
- 229940050526 hydroxyethylstarch Drugs 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 241001535291 Analges Species 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 11
- 230000009469 supplementation Effects 0.000 description 11
- 230000008733 trauma Effects 0.000 description 11
- 108010094028 Prothrombin Proteins 0.000 description 10
- 102100027378 Prothrombin Human genes 0.000 description 10
- 108010000499 Thromboplastin Proteins 0.000 description 10
- 102000002262 Thromboplastin Human genes 0.000 description 10
- 229940039716 prothrombin Drugs 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- -1 FXla Proteins 0.000 description 9
- 108010018823 anti-inhibitor coagulant complex Proteins 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 208000007536 Thrombosis Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229940105776 factor viii inhibitor bypassing activity Drugs 0.000 description 8
- 238000010606 normalization Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 206010002091 Anaesthesia Diseases 0.000 description 7
- 241000282887 Suidae Species 0.000 description 7
- 230000037005 anaesthesia Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 238000001647 drug administration Methods 0.000 description 7
- 206010067125 Liver injury Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 238000001949 anaesthesia Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000084 colloidal system Substances 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 231100000753 hepatic injury Toxicity 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 229940112216 novoseven Drugs 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 238000006116 polymerization reaction Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 108010013773 recombinant FVIIa Proteins 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 230000004872 arterial blood pressure Effects 0.000 description 4
- 238000010241 blood sampling Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000004023 fresh frozen plasma Substances 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 102100022641 Coagulation factor IX Human genes 0.000 description 3
- 208000005189 Embolism Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101800004937 Protein C Proteins 0.000 description 3
- 102000017975 Protein C Human genes 0.000 description 3
- 101800001700 Saposin-D Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 210000001105 femoral artery Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- 229960000856 protein c Drugs 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000009424 thromboembolic effect Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102100026735 Coagulation factor VIII Human genes 0.000 description 2
- 206010067787 Coagulation factor deficiency Diseases 0.000 description 2
- 208000028399 Critical Illness Diseases 0.000 description 2
- 239000003154 D dimer Substances 0.000 description 2
- 201000003542 Factor VIII deficiency Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
- 239000012891 Ringer solution Substances 0.000 description 2
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 239000004019 antithrombin Substances 0.000 description 2
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008238 biochemical pathway Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 238000009530 blood pressure measurement Methods 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 2
- 238000011278 co-treatment Methods 0.000 description 2
- 238000007820 coagulation assay Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 108010052295 fibrin fragment D Proteins 0.000 description 2
- 238000002637 fluid replacement therapy Methods 0.000 description 2
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 2
- 125000000291 glutamic acid group Chemical class N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000009429 hemophilia B Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 201000005665 thrombophilia Diseases 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229940075601 voluven Drugs 0.000 description 2
- 108010047303 von Willebrand Factor Proteins 0.000 description 2
- 102100036537 von Willebrand factor Human genes 0.000 description 2
- 229960001134 von willebrand factor Drugs 0.000 description 2
- 229960005080 warfarin Drugs 0.000 description 2
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- JWDYCNIAQWPBHD-UHFFFAOYSA-N 1-(2-methylphenyl)glycerol Chemical compound CC1=CC=CC=C1OCC(O)CO JWDYCNIAQWPBHD-UHFFFAOYSA-N 0.000 description 1
- 208000002004 Afibrinogenemia Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000001593 Bernard-Soulier syndrome Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 102000016550 Complement Factor H Human genes 0.000 description 1
- 108010053085 Complement Factor H Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000028702 Congenital thrombocyte disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-ZXXMMSQZSA-N D-iditol Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-ZXXMMSQZSA-N 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010074105 Factor Va Proteins 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 101100335629 Homo sapiens FH gene Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 208000004221 Multiple Trauma Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000013544 Platelet disease Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 206010051077 Post procedural haemorrhage Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 206010058151 Pulseless electrical activity Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 201000000839 Vitamin K Deficiency Bleeding Diseases 0.000 description 1
- 102000004210 Vitamin K Epoxide Reductases Human genes 0.000 description 1
- 108090000779 Vitamin K Epoxide Reductases Proteins 0.000 description 1
- 206010047634 Vitamin K deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000016804 acquired coagulation factor deficiency Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940124326 anaesthetic agent Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940070435 anti-inhibitor coagulant complex Drugs 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 229950003616 azaperone Drugs 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 229960000182 blood factors Drugs 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 108090001015 cancer procoagulant Proteins 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000005796 circulatory shock Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- 208000014763 coagulation protein disease Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 201000007182 congenital afibrinogenemia Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- QLBHNVFOQLIYTH-UHFFFAOYSA-L dipotassium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QLBHNVFOQLIYTH-UHFFFAOYSA-L 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940106780 human fibrinogen Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000012977 invasive surgical procedure Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- GVEAYVLWDAFXET-XGHATYIMSA-N pancuronium Chemical compound C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 GVEAYVLWDAFXET-XGHATYIMSA-N 0.000 description 1
- 229960005457 pancuronium Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960003733 phenylephrine hydrochloride Drugs 0.000 description 1
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- IHEHEFLXQFOQJO-UHFFFAOYSA-N piritramide Chemical compound C1CC(C(=O)N)(N2CCCCC2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 IHEHEFLXQFOQJO-UHFFFAOYSA-N 0.000 description 1
- 229960001286 piritramide Drugs 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 208000004521 platelet storage pool deficiency Diseases 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- 230000026447 protein localization Effects 0.000 description 1
- 108010014806 prothrombinase complex Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000005163 right hepatic lobe Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003354 serine derivatives Chemical class 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000003356 suture material Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000012032 thrombin generation assay Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 208000016794 vitamin K deficiency hemorrhagic disease Diseases 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 229940019333 vitamin k antagonists Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39022410P | 2010-10-06 | 2010-10-06 | |
| PCT/EP2011/066241 WO2012045569A1 (en) | 2010-10-06 | 2011-09-19 | Factor ii and fibrinogen for treatment of haemostatic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG188639A1 true SG188639A1 (en) | 2013-05-31 |
Family
ID=44677879
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013021498A SG188639A1 (en) | 2010-10-06 | 2011-09-19 | Factor ii and fibrinogen for treatment of haemostatic disorders |
| SG10201508159SA SG10201508159SA (en) | 2010-10-06 | 2011-09-19 | Factor II And Fibrinogen For Treatment Of Haemostatic Disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201508159SA SG10201508159SA (en) | 2010-10-06 | 2011-09-19 | Factor II And Fibrinogen For Treatment Of Haemostatic Disorders |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9433664B2 (https=) |
| EP (1) | EP2624859B1 (https=) |
| JP (1) | JP6000259B2 (https=) |
| KR (1) | KR20130136988A (https=) |
| CN (1) | CN103221061A (https=) |
| AU (1) | AU2011313505B2 (https=) |
| BR (1) | BR112013008034A2 (https=) |
| CA (1) | CA2812888A1 (https=) |
| DK (1) | DK2624859T3 (https=) |
| ES (1) | ES2625153T3 (https=) |
| HU (1) | HUE033204T2 (https=) |
| MX (1) | MX343784B (https=) |
| PL (1) | PL2624859T3 (https=) |
| RU (1) | RU2606155C2 (https=) |
| SG (2) | SG188639A1 (https=) |
| WO (1) | WO2012045569A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12171463B2 (en) | 2008-10-03 | 2024-12-24 | Femasys Inc. | Contrast agent generation and injection system for sonographic imaging |
| CA2812888A1 (en) | 2010-10-06 | 2012-04-12 | Medimmune Limited | Factor ii and fibrinogen for treatment of haemostatic disorders |
| IL230150A0 (en) * | 2013-12-24 | 2014-09-30 | Omrix Biopharmaceuticals Ltd | One-component fibrin glue containing zymogens |
| SG10201912497WA (en) * | 2017-02-09 | 2020-02-27 | Csl Behring Gmbh | A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings |
| CN116059431A (zh) * | 2021-10-29 | 2023-05-05 | 丁琴琴 | 一种含凝血因子的双层止血敷料及其制备方法 |
| WO2023220412A1 (en) * | 2022-05-13 | 2023-11-16 | Cedars-Sinai Medical Center | Hemostatic monitor |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3165600D1 (en) | 1980-01-28 | 1984-09-27 | Baxter Travenol Lab | Prothrombin-containing therapeutic compositions and methods of producing enzymatically active blood clotting factors from prothrombin-containing blood fractions |
| US4501731A (en) | 1983-06-27 | 1985-02-26 | Tishkoff Garson H | Treatment of disparate bleeding disorders with factor X zymogen |
| DE4430204A1 (de) | 1994-08-26 | 1996-02-29 | Behringwerke Ag | Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung |
| SI0796623T1 (en) | 1996-03-20 | 2005-10-31 | Baxter Aktiengesellschaft | Pharmaceutical preparation for the treatment of blood coagulation disorders |
| AT409334B (de) | 1997-09-19 | 2002-07-25 | Immuno Ag | Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren |
| US7094428B2 (en) | 2000-06-16 | 2006-08-22 | The University Of Medicine And Dentistry Of New Jersey | Hemostatic compositions, devices and methods |
| US6825323B2 (en) | 2001-01-10 | 2004-11-30 | The United States Of America As Represented By The Secretary Of The Army | Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same |
| EP1359936B1 (en) | 2001-02-05 | 2008-02-20 | Novo Nordisk Health Care AG | Combined use of factor vii polypeptides and factor viii polypeptides |
| US20060025336A1 (en) | 2001-07-16 | 2006-02-02 | Novo Nordisk A/S | Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides |
| CZ200439A3 (cs) | 2001-07-20 | 2005-03-16 | Novo Nordisk A/S | Farmaceutický prostředek obsahující polypeptidy faktoru Vll a polypeptidy faktoru XI |
| US20040101546A1 (en) * | 2002-11-26 | 2004-05-27 | Gorman Anne Jessica | Hemostatic wound dressing containing aldehyde-modified polysaccharide and hemostatic agents |
| EP1587424A4 (en) | 2002-12-31 | 2012-01-25 | Marinepolymer Tech Inc | Bleeding Compounds and their uses |
| GB0324044D0 (en) | 2003-10-14 | 2003-11-19 | Astrazeneca Ab | Protein |
| US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
| PL1748781T3 (pl) | 2004-05-27 | 2013-05-31 | Baxter Int | Sposoby do leczenia zaburzeń związanych z krwawieniem z zastosowaniem siarczanowanych polisacharydów |
| EP1893230A2 (en) | 2005-04-26 | 2008-03-05 | Maxygen Holdings Ltd. | Use of modified factor vii for treating bleeding |
| MX336958B (es) | 2005-11-15 | 2016-02-05 | Philadelphia Children Hospital | Metodos y composiciones para modular la hemostasia. |
| JP2009528843A (ja) * | 2006-03-06 | 2009-08-13 | ヒューマジーン・インコーポレイテッド | 組換えヒトトロンビンおよびフィブリノゲンの調製法 |
| US20080014251A1 (en) | 2006-07-14 | 2008-01-17 | Advanced Vascular Dynamics | Hemostatic compound and its use |
| US20090148502A1 (en) | 2006-10-23 | 2009-06-11 | Hemo Nanoscience, Llc | Compositions and methods for treating lacerations, abrasions, avulsions, burns, ulcers, and cases of excessive bleeding |
| EP1935429A1 (en) | 2006-12-22 | 2008-06-25 | CSL Behring GmbH | Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates |
| US20080267940A1 (en) | 2007-03-30 | 2008-10-30 | Mohammed Syed F | Methods of making concentrated fibrinogen containing compositions and associated systems for preparing fibrin glue |
| BRPI0810172A2 (pt) | 2007-04-13 | 2014-10-14 | Catalyst Biosciences Inc | Polipeptídeos de fator vii modificado e seus usos |
| US8852558B2 (en) | 2008-03-11 | 2014-10-07 | Materials Modification, Inc. | In situ formation of an artificial blockage to control bleeding by polymer expansion with hydrogen peroxide and platinum catalyst |
| EP2337793A4 (en) | 2008-10-08 | 2013-04-10 | Thrombodyne Inc | METHOD FOR PRODUCING CONCENTRATED FIBRINOGEN AND PLAIN-CONTAINING COMPOSITIONS |
| CA2812888A1 (en) | 2010-10-06 | 2012-04-12 | Medimmune Limited | Factor ii and fibrinogen for treatment of haemostatic disorders |
-
2011
- 2011-09-19 CA CA2812888A patent/CA2812888A1/en not_active Abandoned
- 2011-09-19 SG SG2013021498A patent/SG188639A1/en unknown
- 2011-09-19 AU AU2011313505A patent/AU2011313505B2/en not_active Ceased
- 2011-09-19 BR BR112013008034A patent/BR112013008034A2/pt not_active IP Right Cessation
- 2011-09-19 HU HUE11761051A patent/HUE033204T2/en unknown
- 2011-09-19 SG SG10201508159SA patent/SG10201508159SA/en unknown
- 2011-09-19 ES ES11761051.9T patent/ES2625153T3/es active Active
- 2011-09-19 JP JP2013532104A patent/JP6000259B2/ja not_active Expired - Fee Related
- 2011-09-19 CN CN2011800479754A patent/CN103221061A/zh active Pending
- 2011-09-19 US US13/877,854 patent/US9433664B2/en not_active Expired - Fee Related
- 2011-09-19 KR KR1020137008520A patent/KR20130136988A/ko not_active Ceased
- 2011-09-19 DK DK11761051.9T patent/DK2624859T3/en active
- 2011-09-19 PL PL11761051T patent/PL2624859T3/pl unknown
- 2011-09-19 EP EP11761051.9A patent/EP2624859B1/en not_active Revoked
- 2011-09-19 MX MX2013003715A patent/MX343784B/es active IP Right Grant
- 2011-09-19 WO PCT/EP2011/066241 patent/WO2012045569A1/en not_active Ceased
- 2011-09-19 RU RU2013120033A patent/RU2606155C2/ru not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK2624859T3 (en) | 2017-06-06 |
| KR20130136988A (ko) | 2013-12-13 |
| JP6000259B2 (ja) | 2016-09-28 |
| ES2625153T3 (es) | 2017-07-18 |
| PL2624859T3 (pl) | 2017-09-29 |
| US20130280236A1 (en) | 2013-10-24 |
| EP2624859B1 (en) | 2017-03-01 |
| HUE033204T2 (en) | 2017-11-28 |
| AU2011313505B2 (en) | 2015-09-17 |
| WO2012045569A9 (en) | 2016-01-07 |
| WO2012045569A1 (en) | 2012-04-12 |
| SG10201508159SA (en) | 2015-10-29 |
| JP2013538863A (ja) | 2013-10-17 |
| EP2624859A1 (en) | 2013-08-14 |
| BR112013008034A2 (pt) | 2016-06-14 |
| MX343784B (es) | 2016-11-23 |
| US9433664B2 (en) | 2016-09-06 |
| RU2013120033A (ru) | 2014-11-20 |
| CN103221061A (zh) | 2013-07-24 |
| MX2013003715A (es) | 2013-09-26 |
| RU2606155C2 (ru) | 2017-01-10 |
| CA2812888A1 (en) | 2012-04-12 |
| AU2011313505A1 (en) | 2013-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Moore et al. | Trauma-induced coagulopathy | |
| Shami et al. | Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy | |
| Besser et al. | Haemostatic management of cardiac surgical haemorrhage | |
| Ahonen | The role of recombinant activated factor VII in obstetric hemorrhage | |
| Chee et al. | Management of bleeding in vascular surgery | |
| EP2624859B1 (en) | Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy | |
| Valla et al. | The coagulation system in patients with end‐stage liver disease | |
| Sharma et al. | Management of a postpartum coagulopathy using thrombelastography | |
| Solomon et al. | Fibrin formation is more impaired than thrombin generation and platelets immediately following cardiac surgery | |
| US20100279939A1 (en) | Recombinant human fibrinogen for treatment of bleeding in trauma and platelet disorders | |
| Rayatdoost et al. | The use of large animal models in trauma and bleeding studies | |
| US20090018082A1 (en) | Use of Factor VIIa or Factor VIIa Equivalents for Treating Trauma | |
| Pusateri et al. | Effects of increasing doses of activated recombinant factor VII on haemostatic parameters in swine | |
| HK1188391A (en) | Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy | |
| HK1188391B (en) | Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy | |
| Le Sache et al. | Recombinant activated factor VII and prothrombin complex concentrates have different effects on bleeding and arterial thrombosis in the haemodiluted rabbit | |
| JP2001181204A (ja) | 血液凝固異常に基づく疾患の治療・予防用医薬組成物 | |
| Clevenger et al. | Intraoperative management of coagulation | |
| Shettar et al. | Coagulation Management in End-Stage Liver Disease | |
| Smith | Coagulopathy in Cirrhotic | |
| Parameswaran et al. | The use of recombinant factor VIIa in gastrointestinal bleeding | |
| Perzborn et al. | C0139 Reversal of rivaroxaban-induced prolongation of clotting time with prothrombin complex concentrate (PCC), activated prothrombin complex concentrate (aPCC) and recombinant Factor VIIa (rFVIIa) in vitro | |
| Quijada et al. | Organ and metabolic complications: Bleeding disorders in renal failure | |
| Jenny | Unlimited DISTRIBUTION STATEMENT A | |
| Pusateri et al. | Effects of Increasing Doses of Activated Recombinant Factor VII (rFVIIa) on Hemostatic Parameters in Swine |